HomeStock ScreenerJubilant Pharmova

Jubilant Pharmova Share Price | Jubilant Pharmova Stock Screener

JUBLPHARMA Pharmaceuticals
Share Price NSE
₹965.35
▼ -5.45 (-0.56%)
2026-07-24 00:00:00
Share Price BSE
₹962.00
▼ -8.85 (-0.91%)
2026-07-24 00:00:00
As of July 24, 2026, the Jubilant Pharmova share price (NSE: JUBLPHARMA) is ₹965.35 on NSE and ₹962.00 on BSE, down 0.56% from the previous close, with shares trading between ₹950.60 and ₹971.10, and a 52-week range of ₹807.65–₹1,236.30. Analyse Jubilant Pharmova stock price data download and track historical price performance. Use the Jubilant Pharmova stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Jubilant Pharmova Market Cap ₹16,308.00 Cr.
JUBLPHARMA P/E Ratio (TTM) 40.97
Jubilant Pharmova P/B Ratio 2.30
EPS (TTM) ₹25.15
Dividend Yield 0.49%
Debt to Equity 0.55
JUBLPHARMA 52 Week High ₹1236.30
Jubilant Pharmova 52 Week Low ₹807.65
Operating Margin 14.00%
Profit Margin 5.18%
JUBLPHARMA Revenue (TTM) ₹2,296.00
EBITDA ₹332.00
Net Income ₹119.00
Total Assets ₹15,523.00
Total Equity ₹7,093.00

Jubilant Pharmova Share Price Chart

Screen Jubilant Pharmova share price with an interactive chart. Analyse JUBLPHARMA price trends and volatility across different timeframes.

Jubilant Pharmova Company Profile - Fundamental Screener

Screen Jubilant Pharmova company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for JUBLPHARMA shares.
Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company. It operates in segments including Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company manufactures and supplies Active Pharmaceutical Ingredients, Solid Dosage Formulations, Radiopharmaceuticals, and...more
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
Chairperson/CEO Shyam S Bhartia
ISIN INE700A01033

Jubilant Pharmova Balance Sheet Screener

Screen JUBLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017
Assets
Total Assets 15,523 12,756 11,549 11,157 9,991 8,918 12,522 11,469 9,618 9,041
Current Assets 4,109 3,577 3,876 3,762 3,509 2,953 5,038 4,585 3,190 2,948
Fixed Assets 8,180 5,176 5,091 5,183 4,871 4,609 6,340 5,648 5,401 5,107
Liabilities
Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 5,888 4,353 4,238 3,993 3,083 3,128 4,299 4,570 3,578 3,968
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0
Shareholders' Equity
Total Equity 7,093 6,239 5,421 5,392 5,316 4,742 5,604 4,809 4,035 3,389
Share Capital 16 16 16 16 16 16 16 16 16 16
Reserves & Surplus 7,077 6,239 5,418 5,383 5,303 4,726 5,588 4,793 4,071 3,421

Jubilant Pharmova Income Statement Screener - Profit & Revenue Analysis

Screen Jubilant Pharmova income statement and profit fundamentals. Analyze JUBLPHARMA quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Jubilant Pharmova share price evaluation.
Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec 2022-Mar 2022-Jun
Revenue 2,296 1,928 1,891 1,968 2,137 1,764 2,130 1,764 1,823 1,682 1,575 1,686 1,714 1,513 1,452
Expenses 1,964 1,587 1,611 1,631 1,873 1,656 1,480 1,477 1,554 1,459 1,419 1,439 1,459 1,280 1,259
EBITDA 332 341 280 337 264 108 650 287 269 223 156 247 255 233 192
Operating Profit % 14.00% 17.00% 14.00% 17.00% 12.00% 5.00% 14.00% 15.00% 14.00% 12.00% 9.00% 14.00% 12.00% 15.00% 13.00%
Depreciation 117 95 98 105 121 101 91 91 91 271 90 97 95 101 95
Interest 57 53 49 50 56 73 71 61 56 56 62 66 71 40 40
Profit Before Tax 176 206 154 190 93 -54 500 144 131 -86 25 98 101 106 69
Tax 57 55 52 70 38 8 18 42 30 14 19 36 35 47 22
Net Profit 119 151 103 120 56 -62 482 103 101 -101 6 62 66 59 47
EPS 7.55 9.71 6.49 7.59 3.52 -3.69 30.44 6.47 6.37 -6.15 0.40 3.94 4.22 3.74 2.96

Jubilant Pharmova Cash Flow Screener - Liquidity Fundamentals

Screen JUBLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March
Operating Activities 1,072 971 661 838 1,784 1,543 1,122 1,303 1,269 1,099
Investing Activities 513 -596 -474 -323 -727 -267 -1,018 -614 -465 -309
Financing Activities -1,453 -433 -157 -33 -1,709 -1,050 657 -901 -686 -843
Net Cash Flow 132 -58 30 482 -652 225 761 -212 117 -52

Jubilant Pharmova Shareholding Pattern Screener

See Jubilant Pharmova shareholding pattern with promoter, FII, and DII holdings. Check Jubilant Pharmova promoter holding and ownership changes for JUBLPHARMA on TickJournal.
Item 2026-Mar 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept
Promoter Holding 47.68% 50.68% 47.68% 47.68% 47.68% 50.68% 50.68% 50.68%
FII Holding 15.90% 17.22% 17.40% 16.57% 15.96% 19.06% 19.49% 17.94%
DII Holding 11.62% 7.05% 9.53% 10.52% 11.22% 3.78% 4.07% 5.66%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 17.57% 17.75% 17.97% 18.02% 17.85% 18.71% 17.79% 18.09%
Other Holding 7.23% 7.31% 7.42% 7.22% 7.29% 7.77% 7.97% 7.63%
Shareholder Count 86,347 96,526 99,673 93,336 90,133 92,264 81,992 89,456

Jubilant Pharmova Share Dividend Screener - Share Yield Analysis

Check Jubilant Pharmova dividend history with payout and yield data. View Jubilant Pharmova dividend details including ex-dates and amounts for JUBLPHARMA stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹5.00 0.61%
2024-March ₹5.00 0.56%
2023-March ₹5.00 0.88%
2022-March ₹5.00 1.79%
2021-March ₹5.00 1.29%
2020-March ₹5.00 0.73%
2019-March ₹4.50 1.81%
2018-March ₹3.00 0.45%
2017-March ₹3.00 0.36%

Jubilant Pharmova Stock Index Membership

See which indices include Jubilant Pharmova stock. Check JUBLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP

Jubilant Pharmova Market Events Screener - Corporate Actions

Get Jubilant Pharmova corporate actions including splits, bonuses, and buybacks. Check Jubilant Pharmova stock events that may affect JUBLPHARMA share price.
Announcement Date Record Date Event Type Information Price Impact
2026-07-24 2026-07-24 Dividend ₹ 5.00 /share 1.05%
2026-05-22 2026-05-22 Quarterly Result Announcement NA 6.91%
2026-02-06 2026-02-06 Quarterly Result Announcement NA 2.93%
2025-10-31 2025-10-31 Quarterly Result Announcement NA 1.90%
2025-08-29 2025-08-29 Annual General Meeting NA -7.13%
2025-07-29 2025-07-29 Quarterly Result Announcement NA -2.98%
2025-07-25 2025-07-25 Dividend ₹ 5.00 /share 29.75%
2025-05-16 2025-05-16 Quarterly Result Announcement NA 1.03%
2025-01-31 2025-01-31 Quarterly Result Announcement NA 1.84%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -9.79%
2024-08-30 2024-08-30 Annual General Meeting NA 8.43%
2024-08-02 2024-08-02 Dividend ₹ 5.00 /share 23.06%
2023-08-10 2023-08-10 Dividend ₹ 5.00 /share 11.53%
2022-08-11 2022-08-12 Dividend ₹ 5.00 /share -11.02%
2021-08-05 2021-08-06 Dividend ₹ 5.00 /share -22.02%

Jubilant Pharmova Competitors Screener - Peer Comparison

Screen JUBLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 469,406 40.30 61,674 12.69% 11,565 67.08
Divis Laboratories 194,270 75.03 10,560 8.73% 2,520 71.64
Torrent Pharmaceuticals 190,389 75.44 13,886 20.34% 2,138 65.32
Cipla 116,459 29.67 29,045 2.24% 3,870 55.65
Zydus Life Science 115,616 22.25 27,658 17.64% 5,026 60.58
Lupin 113,325 20.85 29,039 26.75% 5,356 59.41
Mankind Pharma 105,967 53.09 14,636 14.85% 1,938 59.45
Dr Reddys Laboratories 102,088 24.31 35,059 3.90% 4,158 35.59
Aurobindo Pharma 89,736 25.44 33,385 3.21% 3,376 55.50
Laurus Labs 84,158 92.82 6,868 22.01% 890 63.63

Jubilant Pharmova Company Announcements - News Screener

Screen JUBLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-07-24 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-24 Shareholder Meeting / Postal Ballot-Notice of Postal Ballot -
2026-07-21 Rectification Order From The Income Tax Department -
2026-07-21 Approval For Grant Of Stock Options/Rsus/Psus -
2026-07-21 Disclosure under Regulation 30A of LODR -
2026-07-02 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-07-01 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-06-30 Receipt Of Rectification Order -
2026-06-29 Closure of Trading Window -
2026-06-26 Tentative Approval For Panto-Prazole Sodium DR -
2026-06-24 Rectification Order Received From Tax Department In The Matter Of Jubilant Generics Ltd -
2026-06-19 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-06-19 Completion Of USFDA Inspection -
2026-05-29 USFDA Inspection Update - Contract Manufacturing Facility At Montreal Canada -
2026-05-27 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-27 Earnings Call Transcript -
2026-05-23 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-05-22 Tax Demand Order Received By Companys Step Down Subsidiary -
2026-05-22 Announcement under Regulation 30 (LODR)-Press Release / Media Release -